Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313079 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Steven E. Coutre.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00313079: Completed Phase 1 study, sponsored by Steven E. Coutre.
NCT00313079 is a Phase 1 study that has completed, run by Steven E. Coutre. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313079, a Phase 1 study, has completed, sponsored by Steven E. Coutre.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
Interventions
- DRUG Vincristine
- DRUG MAb 216
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00313079 record still lists
NCT00313079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Vincristine is the first listed.
NCT00313079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313079 about?
NCT00313079 is a clinical study titled "Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia". A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
What is the current status of trial NCT00313079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00313079?
The interventions under investigation include: Vincristine (DRUG), MAb 216 (DRUG).
Who is sponsoring clinical trial NCT00313079?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00313079's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia